OBJECTIVE: To probe into the effects of atorvastatin calcium combined with trimetazidine on cardiac function in patients with chronic heart failure. METHODS: Totally 100 patients with chronic heart failure admitted into the Fifth Affiliated (Zhuhai) Hospital of Zunyi Medical College from Mar. 2015 to Mar. 2018 were extracted to be divided into obervation group and control group via the random number table, with 50 cases in each group. Both groups received the routine treatment, and the observation group was additionally treated with atorvastatin calcium combined with trimetazidine. The course of treatment was 6 months. Differences of the 6-min walking test, left ventricular systolic end diameter (LVEDS), left ventricular diastolic end diameter (LVEDD), left ventricular ejection fraction (LVEF) and serum N-Terminal B natriuretic peptide propeptide (NT-proBNP) levels before and after treatment were compared between two groups. RESULTS: After treatment for 3 and 6 months, the 6-min walking distance of two groups was significantly higher than that before treatment, and the observation group was significantly longer than the control group, with statistically significant difference (P＜0.05). After treatment for 3 and 6 months, the LVEDS and LVEDD of two groups were significantly lower than those before treatment, and the LVEF increased significantly, the observation group were significantly better than the control group, and the differences were statistically significant (P＜0.05). After treatment for 3 and 6 months, the serum NT-proBNP levels of two groups was significantly lower than that before treatment, and the observation group was significantly lower than the control group, the difference was statistically significant (P＜0.05). CONCLUSIONS: Atorvastatin combined with trimetazidine can significantly improve the cardiac function of patients with chronic heart failure, and the clinical efficacy is remarkable.%目的:探讨阿托伐他汀钙联合曲美他嗪对慢性心力衰竭患者心功能的影响.方法:选取2015年3月至2018年3月遵义医学院第五附属 (珠海) 医院收治的慢性心力衰竭患者100例, 采用随机数字表法分为对照组和观察组, 每组50例.两组患者均给予常规治疗, 观察组患者加用阿托伐他汀钙联合曲美他嗪治疗, 两组患者的疗程均为6个月.比较两组患者的6 min步行试验距离、治疗前后左心室收缩末期内径 (LVEDS) 、左心室舒张末期内径 (LVEDD) 、左心室射血分数 (LVEF) 及血清N末端B型利钠肽原 (NT-proBNP) 水平的差异.结果:治疗3、6个月后, 两组患者6 min步行试验距离较治疗前明显增加, 且观察组患者明显长于对照组, 差异均有统计学意义 (P＜0.05);治疗3、6个月后, 两组患者LVEDS、LVEDD水平较治疗前明显降低, LVEF水平明显升高, 且观察组患者明显优于对照组, 差异均有统计学意义 (P＜0.05);治疗3、6个月后, 两组患者血清NT-proBNP水平较治疗前明显降低, 且观察组患者明显低于对照组, 差异均有统计学意义 (P＜0.05).结论:阿托伐他汀钙联合曲美他嗪能明显改善慢性心力衰竭患者的心功能, 临床疗效显著.
展开▼
